The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.

Details

Ressource 1Download: 20104374.pdf (94.01 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_30FEF31AFC68
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.
Journal
Swiss medical weekly
Author(s)
Bihl F., Alaei M., Negro F.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
20/03/2010
Peer-reviewed
Oui
Volume
140
Number
11-12
Pages
154-159
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Since the arrival of several new antivirals and due to the growing molecular and clinical knowledge of hepatitis B virus (HBV) infection, therapy of hepatitis B has become complex. Clinical guidelines aim at streamlining medical attitudes: in this respect, the European Association for the Study of the Liver (EASL) recently issued clinical practice guidelines for the management of chronic hepatitis B. Guidelines made by international experts need however to be adapted to local health care systems. Here, we summarise the EASL guidelines with some minor modifications in order to be compatible with the particular Swiss situation, while discussing in more detail some aspects. Chronic hepatitis B is a complex disease with several phases where host and viral factors interact: the features of this continuous interplay need to be evaluated when choosing the most appropriate treatment. The EASL guidelines recommend, as first-line agents, using the most potent antivirals available with the optimal resistance profile, in order to abate HBV DNA as rapidly and as sustainably as possible. Once therapy has been started, the infection evolves and resistant viral strains may emerge. Rescue therapy needs to be started early with more potent agents lacking cross-resistance.

Keywords
Antiviral Agents/therapeutic use, Comorbidity, Drug Resistance, Female, HIV Infections, Health Personnel, Hepatitis B virus/drug effects, Hepatitis B virus/genetics, Hepatitis B, Chronic/drug therapy, Hepatitis B, Chronic/physiopathology, Hepatitis B, Chronic/virology, Humans, Immunocompromised Host, Liver Cirrhosis/prevention & control, Male, Practice Guidelines as Topic, Practice Patterns, Physicians', Pregnancy, Switzerland
Pubmed
Web of science
Create date
14/02/2011 8:47
Last modification date
20/08/2019 13:15
Usage data